Business
Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Tr...
About this update from Resverlogix Corp.
[{"type":"text","content":"\n\n\n\nResverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prnml40{\nMARGIN-LEFT:3.33em\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, May 30, 2017\n\n\n\nApabetalone expands in to first orphan disease clinical trial in patients with Fabry disease\n\n\n\nCALGARY, May 30, 2017 /CNW/ - Resverlogix Corp. (\"Resverlogix\" or the \"Company\") (TSX:RVX) today announced that it has received approval from Health Canada, Therapeutic Products Directorate, to proceed with a clinical trial with its lead compound apabetalone in patients with Fabry disease.\n\nDonald McCaffrey, President and CEO, stated, \"We are extremely pleased to receive approval for this clinical trial in Canada. Canada possesses some of the world's preeminent experts in the orphan Fabry disease field and a well-established patient registry. Working with us throughout the trial are Dr. Michael West, Principal Investigator, Canadian Fabry Disease Initiative, Professor, Department of Medicine, Dalhousie University, Halifax NS and Dr. Aneal Khan, Associate Professor, Departments of Medical Genetics, Paediatrics, Alberta Children's Hospital, Calgary, AB. Apabetalone is known to regulate key biomarkers associated with this rare disease and may potentially offer an alternative for patients with this rare disorder.\"\n\nFabry Disease Clinical Trial Summary\n\nThis is an open-label, exploratory clinical study to assess the patient safety and effect on key biomarkers of apabetalone in subjects with Fabry disease for up to 16 weeks.\n\nThe primary objective of the study is to evaluate the safety and tolerability of apabetalone in patients with Fabry disease. Secondary objectives include evaluating the effect of apabetalone in subjects with Fabry disease as determined by change in key biomarkers including alkaline phosphatase (ALP), high-sensitivity C-reactive protein (hs-CRP), and other well-known markers for chronic kidney disease.\n\nThe study population will consist of two cohorts:...